Trials
1 active
4 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- How it’s given
- “All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.”In the company’s words, NCT06450886 on ClinicalTrials.gov
- Tested for
- Inclusion Body Myositis (IBM)
- Main trialPhase 2/3
- “ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80…”In the company’s words, NCT06450886 on ClinicalTrials.gov
- Other names
- ABC008
Coming up1
- Jan 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | Jan 2029 | Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis | |
| Phase 2/3Completed | 6 Nov 2025 | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | |
| Phase 1/2Completed | 28 Aug 2025 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | |
| Phase 1Completed | 10 Jan 2025 | A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026